TRex Bio Aims for $133 Million IPO with Support from Eli Lilly
TRex Bio (TRXB), backed by pharmaceutical giant Eli Lilly (LLY), has filed to raise up to $133 million in a U.S. initial public offering on Nasdaq. The biotech firm, which focuses on developing anti-inflammatory drugs, revealed further details about its IPO through an SEC filing. The company is seeking capital for research and development of its drug pipeline, with Eli Lilly's involvement signaling confidence in TRex Bio’s therapeutic approach. While the exact pricing has not yet been set, the offering highlights growing investor interest in biotech innovation targeting inflammation-related diseases. This IPO could attract attention from both institutional investors and pharmaceutical sector stakeholders due to the potential for new treatments and strategic partnerships.
Tickers: $LLY
Topics: biotech ipo securities filing